Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
07:30am, Tuesday, 03'rd Dec 2024
AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today announced th
Single intrathecal dose of Rhenium ( 186 Re) Obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (LM) patients Achieves up to 8x absorbed radiation dose
Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal meta
CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and c
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript
02:45pm, Saturday, 16'th Nov 2024
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2024 Earnings Call Transcript November 14, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - VP and CFO Conference Call Part
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
04:15pm, Thursday, 14'th Nov 2024
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium ( 186 Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive R
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
07:30am, Wednesday, 06'th Nov 2024
AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central ner
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
07:30am, Tuesday, 05'th Nov 2024
AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advance
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
07:30am, Tuesday, 29'th Oct 2024
Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium ( 186 Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development Compa
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
07:30am, Tuesday, 01'st Oct 2024
Rhenium ( 186 Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceed
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
07:30am, Wednesday, 18'th Sep 2024
AUSTIN, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeuti
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
07:30am, Wednesday, 04'th Sep 2024
AUSTIN, Texas, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeuti
Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript
09:55pm, Wednesday, 14'th Aug 2024
Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
04:16pm, Wednesday, 14'th Aug 2024
Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium ( 186 Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
07:30am, Tuesday, 13'th Aug 2024
Plus' CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytol
